Vetter Achieves Top Sustainability Rating and Expands Climate Goal Commitments

Vetter Achieves Top Sustainability Rating and Expands Climate Goal Commitments

Recent recognitions reinforce Vetter’s continued investment in renewable energy projects

• Awarded EcoVadis Platinum rating for 2025
• Received validation from Science Based Targets initiative (SBTi)
• Renewable energy projects support ambitious sustainability strategy

RAVENSBURG, Germany, January 21, 2026/ Biotech Newswire / -- Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has strengthened its sustainability strategy with distinguished recognitions: the internationally renowned EcoVadis Platinum rating as well as the official validation of its emission reduction targets by the Science Based Targets initiative (SBTi). Both achievements highlight the company’s commitment to climate protection and responsible business practices.

For the fourth consecutive year, Vetter has been recognized by the internationally renowned EcoVadis sustainability ranking, earning Platinum status for 2025 and placing itself among the top 1 percent of all rated companies globally.

The official validation of the emission reduction targets by the SBTi approves Vetter’s ambitious sustainability roadmap: by 2034, the CDMO aims to reduce absolute greenhouse gas emissions from Scope 1 and 2 by 58.8 percent (baseline 2021). These goals align with the Paris Agreement and represent one of the most rigorous standards for corporate climate action worldwide. The planned reductions will be achieved through a comprehensive mix of measures, including technical modernization of facilities and equipment, leveraging energy recovery potentials such as waste heat, and transitioning to lower-carbon energy sources–for example, replacing natural gas with biomethane.

“We are proud of the various steps we are taking to reduce our company’s carbon footprint,” states Managing Director Henryk Badack. “Both the validation by the SBTi and the Platinum rating from EcoVadis emphasize our strategic commitment to both people and planet and bring us one step closer to effective climate protection and to achieving overall sustainabilty goals."

Investing in renewable energy and nature restoration
Moving ahead, the family-owned company continues to invest in renewable energy projects. In 2025, the CDMO expanded its overall photovoltaic capacity, covering 22 percent of electricity needs of the Ravensburg Vetter West site. The company also began using biomethane, saving over 1,000 tons of CO₂ annually. Additional initiatives include removing sealed parking areas to create green spaces under photovoltaic installations—improving local microclimates and enabling natural rainwater infiltration.

“In partnership with a local partner supplying biomethane directly to our sites, we unite climate protection with regional value creation and energy security—while significantly reducing our environmental footprint,” says Gabriel Fischer, Team Lead Environment, Health & Safety / EHS Management Systems. “Alongside this, expanding our photovoltaic capacity and using state-of-the art technology like biomethane further demonstrates that sustainability and innovation can go hand in hand.”

© Vetter Pharma International GmbH: By achieving Platinum status in the EcoVadis ranking Vetter is among the top 1% worldwide.

© Naturenergie Rotachtal GmbH & Co. KG: Local biomethane powers Vetter’s sites–uniting climate protection and regional value.

For high resolution please click the images.

Find the Vetter press kit and more background information here. 

Link to the press release

Semantic keywords: Climate Change; Renewable Energy; Greenhouse Gases; Global Warming; Power Plants; Electricity; Sunlight; Natural Gas; Technology; Pharmaceutical Preparations; Germany; Vetter; Sustainability; EcoVadis Platinum rating; Science Based Targets initiative; SBTi; Emission reduction; Climate protection; Contract Development and Manufacturing Organization; CDMO; Greenhouse gas emissions; Paris Agreement; Renewable energy; Photovoltaic capacity; Biomethane; Carbon footprint; Climate goal; Nature restoration; CO₂; Energy recovery; Waste heat; Lower-carbon energy sources; Environmental footprint

About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the USA. As a global player, the independent pharmaceutical service provider is close to its customers with its own sales locations in the Asia-Pacific markets of Japan, China, South Korea and Singapore. Small and large pharmaceutical and biotech companies around the world rely on the decades of experience, high quality, modern technologies, reliability and commitment of its more than 7,300 employees. In close partnership with its customers, Vetter provides patients around the world with life-enhancing medicines. The CDMO provides support from process development to clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes and cartridges. With innovative solutions, the pharmaceutical service provider develops prefilled injection systems together with its customers to continuously improve patient safety, comfort and compliance. Vetter is a pioneer in the industry when it comes to sustainability and, as a corporate citizen, acts in a socially and ethically responsible manner. The pharmaceutical service provider is a member of the UN Global Compact, the Science Based Target initiative (SBTi) and holds Gold status in the EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, the Frost & Sullivan Customer Value Leadership Award or the award as Best Managed Company underscore the company's commitment to sustainable business. The company, which was founded in Ravensburg in 1950, is still family-owned today. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.

Contact 

Vetter Pharma International GmbH 
Markus Kirchner 
Corporate Spokesperson / Media Relations 
Eywiesenstrasse 5 
88212 Ravensburg 
Germany 
+49 (0)751-3700-3729 
PRnews@vetter-pharma.com 

Source: Biotech Newswire